Gerry Hanna, Marie Curie Chair of Clinical Oncology at Trinity College Dublin, shared a post on LinkedIn about a recent article by Ayal A. Aizer et al. published in Journal of Clinical Oncology:
“Stereotactic Radiosurgery (SRS) is being increasingly used to treat brain metastases (BMs) in patients with small cell lung cancer (SCLC), but what are the outcomes and is this better than whole brain radiotherapy alone (WBRT).
This paper just out in Journal of Clinical Oncology reports survival and safety outcomes on 100 patients with 1-10 BMs:
- Median OS=10.2 months
- 1 yr neurological death rate = 11%
- Symptomatic radionecrosis = 5% (suggesting good safety)
- 78% avoided WBRT.”
Title: Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial
Authors: Ayal A. Aizer, Shyam K. Tanguturi, Diana D. Shi, Paul J. Catalano, Kee-Young Shin, Ivy Ricca, Marciana Johnson, Grant Benham, David E. Kozono, Raymond H. Mak, Lauren Hertan, Fallon Chipidza, Monica Krishnan, Itai Pashtan, Luke Peng, Jack M. Qian, Ron Y. Shiloh, Daniel N. Cagney, Jacob Sands, Paul D. Brown, Patrick Y. Wen, Daphne A. Haas-Kogan, Rifaquat Rahman
Read the Full Article on Journal of Clinical Oncology
More posts featuring Gerry Hanna.